Legend Biotech – Cell Therapy

As a subsidiary of GenScript Biotech Corporation, Legend Biotech (NASDAQ: LEGN) is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncological and other indications. Legend Biotech's team of over 650 employees across the United States, China and Europe, along with differentiated technology, development, and manufacturing strategies and expertise, provides Legend Biotech with the capabilities to discover, create, and manufacture best-in-class cell therapies for patients in need. Legend Biotech has been engaged in a strategic collaboration with Janssen Biotech to develop and commercialize the lead product candidate, LCAR-B38M/JNJ-4528, an investigational BCMA-targeted CAR-T cell therapy for patients living with relapsed or refractory multiple myeloma. This candidate is currently being studied in registrational clinical trials.